依洛尤单抗对急性冠脉综合征患者支架术后再狭窄的影响  

The Effect of Evolocumab on In-stent Restenosis in Patients With Acute Coronary Syndrome

作　　者：高韩斌 GAO Hanbin(Department of Cardiology,The First People's Hospital of Taicang(Taicang Hospital Affiliated to Soochow University),Taicang 215400,Jiangsu,China)

机构地区：[1]太仓市第一人民医院(苏州大学附属太仓医院)心内科,江苏太仓215400

出　　处：《系统医学》2024年第16期71-74,共4页Systems Medicine

基　　金：太仓市第一人民医院2021年度院级科学研究项目(TYY2021YJKY18)。

摘　　要：目的 探讨急性冠脉综合征(acute coronary syndrome,ACS)患者行经皮冠脉介入(percutaneous coronary intervetion,PCI)术后,使用依洛尤单抗强化降脂方案对支架内再狭窄(in-stent restenosis,ISR)发生的干预效果。方法 非随机选取2019年6月—2021年6月太仓市第一人民医院收治的320例急性冠脉综合征患者为研究对象,按照是否使用依洛尤单抗分组,各160例。分为他汀组和他汀类+依洛尤单抗组。对比两组血脂水平、不良事件发生情况及无事件生存率。结果 治疗后两组各项血脂指标水平均低于治疗前,且治疗后他汀类+依洛尤单抗组各项血脂指标水平低于他汀组,差异有统计学意义(P均<0.05);他汀类+依洛尤单抗组不良事件发生率低于他汀组,差异有统计学意义(P<0.05);他汀类+依洛尤单抗组患者无事件生存率为77.50%(124/160),高于他汀组的64.38%(103/160),差异有统计学意义(χ^(2)=6.685,P<0.05)。结论 采取依洛尤单抗加入PCI术后降脂方案中,可有效降低冠脉支架术后再狭窄的发生。Objective To investigate the intervention effect of using an intensified lipid-lowering regimen with evolocumab on in-stent restenosis(ISR) after percutaneous coronary intervention(PCI) in patients with acute coronary syndrome(ACS).Methods A total of 320 patients with acute coronary syndrome admitted to the First People's Hospital of Taicang City from June 2019 to June 2021 were non-randomly selected as the study objects,and divided into 160 patients according to whether or not they were treated with evolocumab.They were divided into statins group and statins + evolocumab group.Blood lipid levels,event-free survival rate and adverse events were compared between the two groups.Results After treatment,the levels of various lipid indexes in both groups were lower than before treatment,and after treatment,the levels of various lipid indexes in statins + evolocumab group were lower than those in statins group,the differences were statistically significant(all P<0.05).The incidence of adverse events in statins + evolocumab group was lower than that in statins group,and the difference was statistically significant(P<0.05).The eventfree survival rate was 77.50%(124/160) in statins + evolocumab group,which was higher than 64.38%(103/160) in statins group,the difference was statistically significant(χ^(2)=6.685,P<0.05).Conclusion The addition of evolocumab to the post PCI lipid-lowering regimen can effectively reduce the occurrence of in-stent restenosis after coronary intervention.

关 键 词：冠心病 依洛尤单抗 支架内再狭窄 调脂策略 

分 类 号：R541[医药卫生—心血管疾病]